Insider Selling: ABIOMED, Inc. (ABMD) Director Sells $142,556.94 in Stock

ABIOMED, Inc. (NASDAQ:ABMD) Director Eric A. Md Rose sold 982 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $145.17, for a total transaction of $142,556.94. Following the completion of the sale, the director now directly owns 13,634 shares of the company’s stock, valued at $1,979,247.78. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Shares of ABIOMED, Inc. (NASDAQ:ABMD) opened at 151.06 on Monday. ABIOMED, Inc. has a 12-month low of $95.14 and a 12-month high of $157.41. The firm’s 50-day moving average price is $149.26 and its 200 day moving average price is $135.36. The firm has a market cap of $6.63 billion, a P/E ratio of 88.34 and a beta of 0.22.

ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.03. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. The firm had revenue of $132.47 million for the quarter, compared to analysts’ expectations of $130.83 million. During the same quarter last year, the business earned $0.29 earnings per share. The company’s revenue was up 28.6% compared to the same quarter last year. On average, equities analysts expect that ABIOMED, Inc. will post $2.24 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://transcriptdaily.com/2017/09/04/insider-selling-abiomed-inc-abmd-director-sells-142556-94-in-stock.html.

A number of equities research analysts have weighed in on ABMD shares. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Piper Jaffray Companies restated a “buy” rating and set a $160.00 price objective on shares of ABIOMED in a report on Tuesday, August 29th. William Blair restated an “outperform” rating on shares of ABIOMED in a report on Thursday, June 8th. Jefferies Group LLC restated a “buy” rating and set a $175.00 price objective on shares of ABIOMED in a report on Tuesday, August 29th. Finally, Zacks Investment Research downgraded ABIOMED from a “buy” rating to a “hold” rating in a report on Monday, August 7th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. ABIOMED has an average rating of “Buy” and an average target price of $158.29.

Institutional investors and hedge funds have recently modified their holdings of the business. William Blair Investment Management LLC boosted its holdings in ABIOMED by 8.9% during the first quarter. William Blair Investment Management LLC now owns 1,121,017 shares of the medical equipment provider’s stock worth $140,351,000 after buying an additional 91,651 shares during the last quarter. Fox Run Management L.L.C. bought a new position in ABIOMED during the second quarter worth about $588,000. World Asset Management Inc boosted its holdings in ABIOMED by 17.0% during the first quarter. World Asset Management Inc now owns 2,844 shares of the medical equipment provider’s stock worth $356,000 after buying an additional 413 shares during the last quarter. Creative Planning raised its position in shares of ABIOMED by 16.4% during the first quarter. Creative Planning now owns 916 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 129 shares during the period. Finally, Municipal Employees Retirement System of Michigan raised its position in shares of ABIOMED by 2.1% during the first quarter. Municipal Employees Retirement System of Michigan now owns 18,700 shares of the medical equipment provider’s stock worth $2,341,000 after purchasing an additional 390 shares during the period. Hedge funds and other institutional investors own 89.84% of the company’s stock.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Insider Buying and Selling by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply